A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: Hematologic, immunologic, and clinical results

Blood

Volumn 87, Issue 5, 1996, Pages 1698-1703

  Younes, Anas ^a   Sarris, Andreas ^a   Consoli, Ugo ^a   Rodriguez, Alma ^a   McLaughlin, Peter ^a   Huh, Yang ^a   Starry, Susan ^a   Cabanillas, Fernando ^a   Andreeff, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; HEMOGLOBIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3 RECEPTOR; RECOMBINANT INTERLEUKIN 3;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; FEMALE; FEVER; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTOMA; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

EID: 0030059693     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.5.1698.bloodjournal8751698     Document Type: Article

References (21)

1. Longo DL: What's the deal with follicular lymphomas? J Clin Oncol 11:202, 1993
2. Yunis JJ, Frizzera G, Oken MM: Multiple recurrent genomic defects in follicular lymphoma. N Engl J Med 316:79, 1987
3. Korsmeyer S: Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 80:879, 1992
4. Yang YC, Clark SC: IL-3. Molecular biology and biologic activities. Hematol Oncol Clin North Am 3:441, 1989
5. Ganser A, Lindemann A, Seipelt G, Ottmann OG, Eder M, Falk S, Herrmann F, Kaltwasser JP, Meusers P, Klausmann M, Frisch J, Schulz G, Mertelsmann R, Hoelzer D: Effects of recombinant IL-3 in aplastic anemia. Blood 76:1287, 1990
6. Ganser A, Lindemann A, Seipelt G, Ottman OG, Hermann F, Eder M, Frisch J, Schulz G, Mertelsmann R, Hoelzer D: Effects of recombinant human IL-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76:666, 1990
7. Aglietta M, Sanavio F, Stacchini A, Morelli S, Fubini L, Severino A, Pasquino P, Volta C, Bretti S, Tafuto S, Zola P, Sismondi P, Sklenar I, Piacibello W, Bussolino F, Gavosto, F: IL-3 in vivo: Kinetic of response of target cells. Blood 82:2054, 1993
8. Fay J, Lazarus H, Herzig R, Saez R, Steven DA, Collins RH, Piñerio LA, Cooper BW, DiCeasare J, Campion M, Felser JM, Herzig G, Bernstein SH: Sequential administration of recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: A phase I/II multicenter study. Blood 84:2151, 1994
9. Orazi A, Cattoretti G, Schiro R, Siena S, Bregni M, Di Nicola M, Gianni AM: Recombinant human IL-3 and recombinant human granulocyte-macrophage colony-stimulating factor administered in vivo after high-dose cyclophosphamide cancer chemotherapy: Effect on hematopoiesis and microenvironment in human bone marrow. Blood 79.2610, 1992
10. Fay JW, Lazaurus H, Herzig R, Saez R, Stevens DA, Collins RH, Piñero LA, Cooper BW, DiCesare J, Campion M, Felser JM, Herzig G, Bernstein SH: Sequential administration of recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: A phase I/II muSticenter study. Blood 84:2151, 1994
11. Clayberger C, Luna-Fineman S, Lee JE, Pillai A, Campbell M, Levy R, Krensky AM: Interleukin 3 is a growth factor for human follicular B cell lymphoma. J Exp Med 175:371, 1992
12. Younes A, Drach J, Katz R, Jendiroba D, Sabourian MH, Sarris AH, Swan F, Jr, Hill D, Cabanillas F, Ford R, Andreeff M: Growth inhibition of follicular small-cleaved-cell lymphoma cells in short-term culture by IL-3. Ann Oncol 5:265, 1994
13. Bhatia A, Olencki T, Finke I, Thomassen MJ, McLain D, Sandstrom K, Tuason L, Levitt D, Young D, Bukowski RM: Phase IA/IB trial of rhIL-3 in patients with refractory malignancies: An immunomodulatory cytokine. Proc Am Assoc Can Res 34:1263, 1993
14. Von Hoff DD, Degen D, Myers LA, Levitt D: Effect of hematopoietic growth factors GMCSF, IL-3, and II-6 on colony-forming units of tumors taken directly from patients. Blood 80:1676, 1992 (Suppl 1)
15. Hirayama F, Clark SC, Ogawa M: Negative regulation of early B lymphopoiesis by interleukin 3 and interleukin 1a. Proc Natl Acad Sci USA 91:469, 1994
16. Paul CC, Bauman MA: Modulation of spontaneous outgrowth of Epstein-Barr virus immortalized B-cell clones by granulocyte-macrophage colony-stimulating factor and IL-3. Blood 75:54, 1990
17. Cockayne DA, Bodine DM, Cline A, Nienhuis AW, Dunbar CE: Transgenic mice expressing antisense IL-3 RNA develop a B-cell lymphoproliferative syndrome or neurologic dysfunction. Blood 84:2699, 1994
18. Kramer MHH, Kluin PM, Wijburg ER, Fibbe WE, Kluin-Nelemans HC: Differentiation of follicular lymphoma cells after autologous bone marrow transplantation and haematopoietic growth factor treatment. Lancet 345:345, 1995
19. Hoffman R: IL-3: A potentially useful agent for treating chemotherapy-related thrombocytopema. J Clin Oncol 11:2057, 1993
20. D'Hondt V, Weynants P, Humblet Y, Thierry G, Canon JL, Beauduin M, Duprez P, Longueville J, Mull R, Chatelain C, Symann M: Dose-dependent IL-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study. J Clin Oncol 11:063, 1993
21. Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JU: Phase I study of recombinant IL-3 in patients with bone marrow failure. J Clin Oncol 9:1241, 1991